Additional challenges to UFH monitoring include patients with heparin resistance or antithrombin III deficiency, for which both aPTT and anti-Xa (and the addition of antithrombin III concentrates in antithrombin III-deficient patients, if clinically indicated) are typically used [27]. The gene discussed is SERPINC1; the disease is hyperinsulinemic hypoglycemia, familial, 4.